



This blend contains CJC-1295 (no DAC), the tetrasubstituted GHRH(1-29) analog also sold as Mod GRF 1-29, together with Ipamorelin, a pentapeptide ghrelin receptor agonist. The identity test on our lot confirms CJC-1295 WITHOUT DAC plus Ipamorelin at 5 mg each. The distinction from CJC-1295 with DAC matters: the DAC version carries a maleimide group that bonds the peptide to albumin and stretches its presence in plasma past 72 hours in rats, while the no-DAC form clears quickly and produces a short burst of GHRH receptor stimulation. The two components in this vial act on different receptors. GHRH analogs work on the GHRH receptor on pituitary somatotrophs, and Ipamorelin works on the GHRP receptor, where it released growth hormone from rat pituitary cells with potency and efficacy similar to GHRP-6 but, unusually for that class, without raising ACTH or cortisol even at amounts more than 200-fold above its effective concentration. Researchers combine the two pathways to study how convergent signals shape growth hormone output.
Structured specifications and handling data
Technical specifications
CJC-1295 without DAC (29aa) + Ipamorelin, Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5aa)C152H252N44O42 (CJC-1295 no DAC) + C38H49N9O5 (Ipamorelin)Stability and handling
Growth hormone release from the pituitary is controlled by two separate inputs, and this blend contains one agonist for each. CJC-1295 without DAC is a modified GHRH(1-29) fragment that binds the GHRH receptor on somatotroph cells and runs the adenylyl cyclase and cyclic AMP cascade. Ipamorelin binds the GHRP receptor instead, the same receptor ghrelin uses. Pharmacological profiling with GHRP and GHRH antagonists confirmed that Ipamorelin works through the GHRP-like receptor rather than the GHRH one, which is what makes the pairing a two-pathway experiment rather than two versions of the same stimulus.
Ipamorelin is the selective member of its class, and that is the reason it appears in blends. In rat pituitary cells it matched GHRP-6 for potency and efficacy, and in conscious swine neither compound moved FSH, LH, prolactin or TSH. The difference showed up in the stress axis: GHRP-6 and GHRP-2 both raised ACTH and cortisol, while Ipamorelin did not, even at amounts more than 200-fold above its effective concentration for growth hormone release. A researcher studying the growth hormone axis gets fewer confounding hormonal changes to control for.
The no-DAC choice in the GHRH half is deliberate. The albumin-bonded version, CJC-1295 with DAC, stays in plasma past 72 hours in rats and, in healthy men, raised trough growth hormone 7.5-fold a week after a single injection while leaving pulse frequency and amplitude unchanged. Without the DAC, stimulation is short, so the pulse pattern itself becomes the variable rather than the floor beneath it. Ipamorelin has also been studied outside the endocrine question entirely, in rodent models of postoperative ileus, where repeated administration shortened the time to first bowel movement and increased fecal output, food intake and weight gain.
Published studies and concise summaries for research review.
AI-generated summary of this research paper below.
Concise answers about laboratory context, handling, and documentation for this compound.
Laboratory compliance notice
All compounds sold by Validated Peptides are intended for in-vitro laboratory research only.
These materials are not approved by the FDA for human or animal use and are not intended for diagnostic, therapeutic, or clinical applications.
Purchasers are responsible for compliant handling, storage, and use within an appropriate laboratory environment.